drugset / Trial / NCT05444153

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

NCT05444153

Phase 3 Withdrawn Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This study compares the medicines semaglutide and empagliflozin in people with newly diagnosed type 2 diabetes and obesity. The study will look mainly at how well the blood sugar and body weight are controlled when participants are taking the study medicine. Participants will either get semaglutide tablets or empagliflozin tablets. Which treatment participants get is decided by chance. Participants will get one tablet per day for 2 years. The study will last for about 2 years and 8 weeks.

Timeline

Start
2022-10-06
Primary completion
2024-10-02
Completion
2025-08-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule 25 mg Oral
Subject Semaglutide Peptide 55 mg Oral